Free Research Reports on APPY, ATHX, CLSN and DCTH Issued by the Bedford Report Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT
© Marketwire 2013
05.02.2013 16:50:28 -
Venaxis Inc. (NASDAQ: APPY) shares surged over 10 percent in trading Monday. The company is focused on obtaining FDA clearance and commercializing its blood-based appendicitis test, APPY1. Venaxis last month began patient enrollment for an APPY1 pivotal study.
Find out more about Venaxis including full access to the free equity report at: www.BedfordReport.com/APPY : http://www.bedfordreport.com/APPY
Athersys, Inc. (NASDAQ: ATHX) shares gained 7 percent on nearly double the average daily volume Monday. The Company currently has several clinical stage programs involving its MultiStem cell therapy product.
Find out more about Athersys including full access to the free equity report at: www.BedfordReport.com/ATHX : http://www.bedfordreport.com/ATHX
Celsion Corporation (NASDAQ: CLSN) shares have plummeted over 80 percent in the apst week after reporting ThermoDox did not meet the primary endpoint of the Phase III HEAT Study in primary liver cancer. The HEAT Study was conducted under a Special Protocol Assessment agreed to with the FDA.
Find out more about Celsion including full access to the free equity report at: www.BedfordReport.com/CLSN : http://www.bedfordreport.com/CLSN
Delcath Systems, Inc. (NASDAQ: DCTH) shares spiked 9.25 percent on nearly 6 million shares traded Monday. The company reported that the German federal reimbursement agency has established a reimbursement pathway for the treatment of patients with liver metastases with the Delcath Hepatic CHEMOSAT Delivery System.
Find out more about Delcath Systems including full access to the free equity report at: www.BedfordReport.com/DCTH : http://www.bedfordreport.com/DCTH
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.
A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.
Equity News Circuit
Email Contact : http://www2.marketwire.com/mw/emailprcntct?id=1F46614867B17AC5